CSIMarket Company Name, Ticker, Customers, else..
 
Intellia Therapeutics Inc   (NTLA)
Other Ticker:  
 
 
Price: $18.5800 $0.79 4.441%
Day's High: $18.6 Week Perf: 4.15 %
Day's Low: $ 17.34 30 Day Perf: -10.11 %
Volume (M): 1,486 52 Wk High: $ 34.87
Volume (M$): $ 27,602 52 Wk Avg: $25.38
Open: $17.57 52 Wk Low: $17.09



 Market Capitalization (Millions $) 1,647
 Shares Outstanding (Millions) 89
 Employees -
 Revenues (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -462
 Cash Flow (TTM) (Millions $) -354
 Capital Exp. (TTM) (Millions $) 12

Intellia Therapeutics Inc
Intellia Therapeutics Inc is a biotechnology company that focuses on developing therapeutic products based on the revolutionary CRISPR gene editing technology. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Intellia aims to utilize CRISPR technology to develop potential cures for genetic diseases by editing and correcting specific genes within the human body. They are also involved in precision oncology, where they aim to develop targeted therapies for various types of cancers. Intellia Therapeutics is known for its innovative research and collaboration with other leading institutions in the field of gene editing.


   Company Address: 40 Erie Street Cambridge 2139 MA
   Company Phone Number: 285-6200   Stock Exchange / Ticker: NASDAQ NTLA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Pioneering Gene Editing Solutions The Launch of Intellia Therapeutics? Phase 3 Study on NTLA-2002 for Hereditary An...

Published Mon, Oct 7 2024 11:30 AM UTC

Hereditary angioedema (HAE) is a genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the face, extremities, gastrointestinal tract, and airway. The root cause of HAE is a deficiency or dysfunction of C1 esterase inhibitor (C1-INH), a protein that regulates various pathways in the immune system and coagulation. Traditional ...
Shares

Intellia Therapeutics Strengthens Gene Editing Frontier with Key Talent Acquisitions,

Published Thu, Oct 3 2024 8:01 PM UTC

Pioneering Talent Acquisition: Intellia Therapeutics Expands Workforce to Drive CRISPR InnovationCAMBRIDGE, Mass. - In a strategic move designed to reinforce its commitment to advancing gene editing technology, Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced on October 1, 2024, the awarding of inducement grants to nine newly hired employees as part of its 2024 Induceme...
Clinical Study

Breaking New Ground in Gene Editing Promising Results from Nexiguran Ziclumeran for ATTR Amyloidosis

Published Tue, Oct 1 2024 11:30 AM UTC

'Abstract' Intellia Therapeutics has embarked on a significant journey in the realm of gene editing with its lead investigational therapy, nexiguran ziclumeran (nex-z, also known as NTLA-2001). Aimed at treating transthyretin (ATTR) amyloidosis, a debilitating condition often resulting in severe cardiac complications, this novel CRISPR-based therapeutic demonstrates the pot...
Clinical Study

Intellia Therapeutics to Unveil Groundbreaking NTLA-2002 Data for Hereditary Angioedema at 2024 ACAAI Conference Amid...

Published Thu, Sep 12 2024 11:30 AM UTC

'Intellia Therapeutics Gears Up for ACAAI Presentation: Promising Data for NTLA-2002 in Hereditary Angioedema Amid Mixed Financial Performance'Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering entity in the field of clinical-stage gene editing, has announced a significant milestone in its ongoing efforts to develop groundbreaking therapies for rare diseases. On Septem...
Clinical Study

Intellia Therapeutics Takes a Giant Leap with NTLA-3001 A New Hope for Alpha-1 Antitrypsin Deficiency and Beyond!...

Published Tue, Jul 30 2024 11:30 AM UTC

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a prominent player in the clinical-stage gene editing landscape, has recently made strides that promise to revolutionize treatment options for rare genetic disorders. The company, headquartered in Cambridge, Massachusetts, announced the authorization of its Clinical Trial Application (CTA) from the United Kingdom's Medicines and He...






Intellia Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com